To observe the safety and effectiveness of fondaparinux sodium applied - on unstable angina pecto-ris patients during the perioperative period of percutaneous transluminal coronary intervention (PCI). [Methods] Two hundred and twenty patients with unstable angina pectoris performed PCI were divided into two groups. Patients in the experimental group( n = 114) accepted 2. 5 mg fondaparinux sodium per day either for 7 days or until their leaving hospital. Patients in the control group (n = 106) accepted enoxaparin 6000 IU twice a day either for 7 days or until their leaving hospital. The major adverse cardiovascular events ( MACE) in hospital and 30 days after PCI were evaluated. The rate of bleeding event was also studied. [Results] There were no statistical differences between these two groups on criminal arteries, multivessel disease, the proportion of TIMI3 grade after PCI, and MACE in hospital or 30 days after PCI(2. 6% vs 1.9% , 4.3% vs 4.7% ). Compared with the control group, no significant difference of the rate of massive hemorrhage was observed in the experimental group, but the rate of subcutaneous bleeding (4. 4% vs 18. 9% ) , hematoma in puncture site (0.9% vs7.5%) and hematuresis (0% vs 4. 7% ) were much less (P<0.05). [Conclusions] Compared with enoxaparin , fondaparinux sodium did not increase MACE. In addition, it could reduce the risk of bleeding. Therefore, fondaparinux sodium was safe and effective on the unstable angina pectoris patients during the perioperative period of PCI.%[目的]观察不稳定型心绞痛患者在经皮冠状动脉介入治疗(PCI)围手术期应用磺达肝癸钠的安全性和有效性.[方法]选择2011年7月—2011年12月因不稳定型心绞痛于大连医科大学附属第二医院行PCI术的患者220例.随机分为两组,试验组(n=114):即围手术期给予磺这肝癸钠2.5 mg/d,皮下注射7d或至出院为止;对照组(n=106):即围手术期给予依诺肝素6 000 IU/次,2次/d皮下注射,注射7d或至出院为止.观察两组患者住院期间及术后30天的主要心血管事件及出血事件的发生率.[结果]两组患者罪犯血管、多支病变比例、术后TIMI3级血流的比例差异均无显著性意义.两组患者住院期间及术后30天的主要心血管事件(2.6％ vs 1.9％,4.3％vs4.7％)差异也无显著性意义.两组患者大出血事件无差别,但是皮下出血(4.4％ vs18.9％)、穿刺部位血肿(0.9％vs 7.5％)及血尿(0％vs 4.7％)的比例,试验组比对照组明显减少(P＜0.05).[结论]与依诺肝素相比,磺达肝癸钠不增加主要心血管事件,且明显降低出血风险.不稳定型心绞痛患者在PCI围手术期应用磺达肝癸钠是安全有效的.
展开▼
